Oncology and Cancer Immunotherapy

Our ultimate vision is to prevent and provide cures for cancer in all its forms. Because no single intervention is likely to achieve this goal, we seek to comprehensively understand the disease, its complexities and its impact on patients.

We have the broadest and most diverse pipeline in oncology with more than 20 immunotherapy molecules. Since 2011, we have introduced 18 oncology medicines. All our efforts are linked by exploring therapeutic combinations and by a commitment to pursuing personalized medicines.

Partnering opportunities we are looking for:

  • Oncogenic drivers

  • DNA Damage Response/ Synthetic lethality

  • Antibody Drug Conjugates

  • Adaptive and innate immunity

  • Neoantigens

  • Stromal biology

  • Cell therapies

Example partnerships

AdaptiveAdaptImmuneBioNTechRelay TherapeuticsVaccibody

Your dedicated partnering leads in Oncology

Interested in partnering with us?

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

See all stories

More Pharma partnering areas

View all areas

Discover more

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement